- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
P0634
PEGINTERFERON IS SUPERIOR TO NUCLEOS(T)IDE ANALOGS FOR
PREVENTION OF HEPATOCELLULAR CARCINOMA IN CHRONIC
HEPATITIS B
K.-H. Liang1, C.-W. Hsu1, M.-L. Chang1, Y.-C. Chen1, M.-W. Lai1,
C.-T. Yeh1. 1Liver Research Center, Chang Gung Memorial Hospital,
Taipei, Taiwan
E-mail: [email protected]
Background and Aims: Clinical and virological factors associated
with occurrence of hepatocellular carcinoma (HCC) in antiviral treatment-
naïve chronic hepatitis B patients have been extensively
studied. However, the clinical usefulness of such data is greatly
limited because of the wide availability of effective antiviral agents.
We aimed to investigate clinical factors associated with HCC
development in treatment-experienced patients.
Methods: 331 patients receiving pre-therapeutic liver biopsy were
included for outcome assessment. Predictors for HCC occurrence
were further analyzed by comparing two age-matched groups
receiving different treatment methods.
Results: Cirrhosis and antiviral treatment method [peginterferon experienced
(PE) versus nucleos(t)ide analog-treatment (NAt) only]
were significantly associated with subsequent HCC occurrence by
initial univariate and multivariate analyses. To further examine
this unexpected finding, 120 age-matched patients were retrieved
from each of the PE and NAt groups for comparison. Baseline
clinical variables showed no statistical difference between the
two treatment groups. PE group had a significant longer
time to HCC than the NAt group (P = 0.0091). The beneficial
effect of peginterferon treatment remained when only cirrhotic
patients were included (P = 0.0437). Additionally, patients receiving
peginterferon alone had a significantly longer time to HCC than
those receiving entecavir alone (P = 0.0111), despite the fact that
serum HBVDNA levels of the entecavir-treated subjects were
kept lower than those treated by peginterferon alone during the
observational period (P < 0.0001).
Conclusions: Peginterferon treatment with or without nucleos(t)ide analog is superior to nucleos(t)ide analogs alone for
the prevention of HCC occurrence in chronic hepatitis B patients
|
|